Treatment of patients with neuropathy and anti‐MAG IgM M‐proteins
Treatment of patients with neuropathy and anti‐MAG IgM M‐proteins
复制标题
神经病患者和抗 MAG IgM M 蛋白的治疗
DOI：
10.1002/ana.410240118
复制
发表时间：
1988
影响因子：
11.2
通讯作者：
G. Scarlato
中科院分区：
文献类型：
--
作者：
E. Nobile‐Orazio;L. Baldini;S. Barbieri;P. Marmiroli;G. Spagnol;E. Francomano;G. Scarlato
5 名患有神经病且 IgM M 蛋白与髓磷脂相关糖蛋白 (MAG) 发生反应的患者接受了细胞抑制剂治疗 10 至 20 个月。在 2 名患者中，血清 M 蛋白和抗 MAG IgM 水平在 12 月份下降，同时神经病变逐渐改善。在其他患者中没有观察到临床改善，也没有观察到抗 MAG IgM 的减少。这些患者的抗 MAG、M 蛋白的 12 月降低与临床改善之间的密切关系支持了 M 蛋白在神经病变中的致病作用。
Five patients with neuropathy and IgM M‐proteins that reacted with myelin‐associated glycoprotein (MAG) were treated for 10 to 20 months with cytostatic agents. In 2 patients, a Decemberrease in serum M‐protein and in anti‐MAG IgM levels coincided with a progressive improvement of neuropathy. No clinical improvement and no Decemberrease of anti‐MAG IgM were observed in the other patients. The close relationship between the Decemberrease of anti‐MAG, M‐proteins and clinical improvement in these patients supports the pathogenetic role of the M‐protein in the neuropathy.
软骨发育不全的死亡率。
影响因子：
9.8
作者：
Hecht,JT;Francomano,CA;Horton,WA;Annegers,JF
通讯作者：
Annegers,JF